Zealand Pharma FIRST LOOK: Roche petrelintide partnership conference call feedback
Zealand hosted a conference call to discuss the co-development and co-commercialisation partnership with Roche for petrelintide announced this morning. Our key learning was that the 50/50 profit share remains in place even if Zealand decides to be less than 50% involved in the commercial roll out, which further points to the attractiveness of the terms the company has been able to secure. We summarise the key takeaways from the conference call.Zealand Pharma is a biotechnology company. Co. is engaged in the discovery development and commercialization of peptide-based medicines. Co.'s pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area are ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.